BR122019021950B8 - métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 - Google Patents

métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3

Info

Publication number
BR122019021950B8
BR122019021950B8 BR122019021950A BR122019021950A BR122019021950B8 BR 122019021950 B8 BR122019021950 B8 BR 122019021950B8 BR 122019021950 A BR122019021950 A BR 122019021950A BR 122019021950 A BR122019021950 A BR 122019021950A BR 122019021950 B8 BR122019021950 B8 BR 122019021950B8
Authority
BR
Brazil
Prior art keywords
methods
lysate
serotype
precipitation
cause
Prior art date
Application number
BR122019021950A
Other languages
English (en)
Other versions
BR122019021950B1 (pt
Inventor
Douglas Bahler Brian
Heller Hughes Erik
Lee Tsu-Shun
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122019021950(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR122019021950B1 publication Critical patent/BR122019021950B1/pt
Publication of BR122019021950B8 publication Critical patent/BR122019021950B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Abstract

a presente invenção refere-se a métodos aperfeiçoados para a redução ou remoção de impurezas protéicas de um complexo lisato ou centrado celular de streptococcus pneumoniae que compreende polissacarídeos sorotipo 3, envolvendo etapas que referem-se a aquecimento pós-lise ou ajuste de ph. em certos métodos, o lisado é aquecido por um tempo e a uma temperatura suficiente para desnaturar proteínas presentes no lisado e provocar sua agregação e precipitação. em uma modalidade, o lisado é aquecido a pelo menos 60oc por pelo menos 30 minutos para causar agregação e precipitação de proteínas, mais particularmente cerca de 60oc a cerca de 70oc por cerca de 30 a cerca de 50 minutos, e ainda mais particularmente a cerca de 65oc por cerca de 40 minutos. em outros métodos, o ph do lisado ou centrado é elevado para pelo menos 8,0 para aperfeiçoar capacidade de filtração, mais particularmente cerca de 8,0 a 8,4, e ainda mais particularmente cerca de 8,2. em métodos adicionais, etapas de aquecimento e ajuste de ph são combinadas para provocar a agregação e precipitação de proteínas, bem como para aperfeiçoar capacidade de filtração dos lisados ou centrados. em outros métodos, o ph do lisado ou centrado é baixado para cerca de 3,0 a cerca de 5,0 para causar agregação e precipitação de proteínas. tais métodos permitem a produção de lisados ou centrados que contêm polissacarídeos sorotipo 3 substancialmente purificados.
BR122019021950A 2006-10-10 2007-10-09 métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3 BR122019021950B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85066506P 2006-10-10 2006-10-10
US60/850,665 2006-10-10
BRPI0717834A BRPI0717834B8 (pt) 2006-10-10 2007-10-09 purificação de polissacarídeos tipo 3 de streptococcus pneumoniae
PCT/US2007/080768 WO2008045852A2 (en) 2006-10-10 2007-10-09 Purification of streptococcus pneumoniae type 3 polysaccharides

Publications (2)

Publication Number Publication Date
BR122019021950B1 BR122019021950B1 (pt) 2021-01-05
BR122019021950B8 true BR122019021950B8 (pt) 2021-07-27

Family

ID=39156240

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019021950A BR122019021950B8 (pt) 2006-10-10 2007-10-09 métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3
BRPI0717834A BRPI0717834B8 (pt) 2006-10-10 2007-10-09 purificação de polissacarídeos tipo 3 de streptococcus pneumoniae

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0717834A BRPI0717834B8 (pt) 2006-10-10 2007-10-09 purificação de polissacarídeos tipo 3 de streptococcus pneumoniae

Country Status (19)

Country Link
US (1) US7659090B2 (pt)
JP (1) JP5260531B2 (pt)
KR (1) KR101467002B1 (pt)
CN (2) CN101522906B (pt)
AT (1) ATE473289T1 (pt)
AU (1) AU2007307800C1 (pt)
BR (2) BR122019021950B8 (pt)
CA (1) CA2665169C (pt)
CL (1) CL2007002909A1 (pt)
DE (1) DE602007007642D1 (pt)
DK (1) DK2074221T3 (pt)
ES (1) ES2346929T3 (pt)
HK (1) HK1174836A1 (pt)
IL (2) IL197782A (pt)
MX (1) MX2009003730A (pt)
PT (1) PT2074221E (pt)
RU (1) RU2460539C2 (pt)
WO (1) WO2008045852A2 (pt)
ZA (1) ZA200902502B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010080486A2 (en) * 2008-12-18 2010-07-15 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
PL2385981T3 (pl) * 2008-12-18 2020-01-31 Wyeth Llc Sposób kontroli masy cząsteczkowej polisacharydów streptococcus pneumoniae z zastosowaniem węgla
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
RU2536248C2 (ru) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
CN102094053B (zh) * 2010-11-26 2013-01-16 兰州生物制品研究所有限责任公司 肺炎链球菌c多糖的纯化方法
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
KR101944960B1 (ko) * 2012-09-07 2019-02-07 에스케이바이오사이언스 주식회사 폐렴 구균 혈청형을 갖는 협막 다당류의 제조방법
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN114887048A (zh) 2014-01-21 2022-08-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
PT3096783T (pt) 2014-01-21 2021-08-16 Pfizer Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
US20160324949A1 (en) 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
BR112017013891B1 (pt) 2015-01-15 2024-01-30 Pfizer Inc Composições imunogênicas para uso em vacinas pneumocócicas
US10836839B2 (en) 2015-04-28 2020-11-17 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
NZ736238A (en) 2015-05-04 2022-07-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2017013548A1 (en) 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2018027123A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112019001971A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composição conjugada de polissacarídeo-proteína pneumocócica multivalente
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CA3048981A1 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
US11197921B2 (en) 2017-01-31 2021-12-14 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
CN110337307A (zh) 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
EP3649247A4 (en) 2017-07-05 2021-03-31 Inventprise, LLC. PURIFICATION OF POLYSACCHARIDES FOR VACCINE PRODUCTION USING LYTIC ENZYMES, TANGENTIAL FILTRATION AND MULTIMODAL CHROMATOGRAPHY
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
EP3678652A4 (en) 2017-09-07 2021-05-19 Merck Sharp & Dohme Corp. ANTIPNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN POLYSACCHARIDE-CARRIER PROTEIN IMMUNOGENIC CONJUGATES
MX2020002557A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
MA51049A (fr) 2017-12-06 2020-10-14 Merck Sharp & Dohme Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
WO2020009993A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
BR112021011961A8 (pt) 2018-12-19 2023-02-07 Merck Sharp & Dohme Composições compreendendo conjugados de polissacarídeo-proteína de streptococcus pneumoniae e métodos de uso dos mesmos
JP2022528158A (ja) 2019-04-10 2022-06-08 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
KR20220042378A (ko) 2019-07-31 2022-04-05 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법
US20210070890A1 (en) * 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
US20230321212A1 (en) 2020-08-26 2023-10-12 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US20230383324A1 (en) * 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413057A (en) * 1980-04-14 1983-11-01 Merck & Co., Inc. Group B streptococcal capsular polysaccharides
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AR022963A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
EP1268844B1 (en) * 2000-03-16 2009-07-29 The Children's Hospital Of Philadelphia Modulating production of pneumococcal capsular polysaccharide
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20050220777A1 (en) * 2003-11-21 2005-10-06 Stefan Roos Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae
PL3466982T3 (pl) * 2005-04-08 2020-11-02 Wyeth Llc Usuwanie zanieczyszczeń z polisacharydu streptococcus pneumoniae poprzez zmianę ph
WO2007084856A2 (en) * 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides

Also Published As

Publication number Publication date
MX2009003730A (es) 2009-04-22
US7659090B2 (en) 2010-02-09
AU2007307800C1 (en) 2014-03-13
CA2665169A1 (en) 2008-04-17
RU2009112453A (ru) 2010-11-20
CN101522906A (zh) 2009-09-02
PT2074221E (pt) 2010-09-06
IL197782A (en) 2014-08-31
BRPI0717834A2 (pt) 2014-06-10
DK2074221T3 (da) 2010-09-06
AU2007307800B2 (en) 2012-12-20
WO2008045852A2 (en) 2008-04-17
IL233893A (en) 2017-04-30
US20080102498A1 (en) 2008-05-01
BRPI0717834B1 (pt) 2020-05-19
KR101467002B1 (ko) 2014-12-01
DE602007007642D1 (de) 2010-08-19
WO2008045852A3 (en) 2008-06-19
RU2460539C2 (ru) 2012-09-10
ZA200902502B (en) 2010-03-31
BR122019021950B1 (pt) 2021-01-05
IL233893A0 (en) 2014-09-30
CN101522906B (zh) 2012-05-30
HK1174836A1 (en) 2013-06-21
CN102648979A (zh) 2012-08-29
BRPI0717834B8 (pt) 2021-05-25
ATE473289T1 (de) 2010-07-15
CN102648979B (zh) 2014-05-14
KR20090071629A (ko) 2009-07-01
CA2665169C (en) 2017-02-21
JP2010505963A (ja) 2010-02-25
IL197782A0 (en) 2011-08-01
CL2007002909A1 (es) 2008-04-18
AU2007307800A1 (en) 2008-04-17
JP5260531B2 (ja) 2013-08-14
ES2346929T3 (es) 2010-10-21

Similar Documents

Publication Publication Date Title
BR122019021950B8 (pt) métodos para a redução ou remoção de impurezas protéicas de um lisado ou centrado celular de streptococcus pneumoniae compreendendo polissacarídeos sorotipo 3
Zha et al. Extraction, purification and antioxidant activities of the polysaccharides from maca (Lepidium meyenii)
ATE537188T1 (de) Serumalbuminbindende proteine
CL2017002029A1 (es) Proceso para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la producción de polisacaridos neumococales (divisional de sol. n°831-08).
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
CA2553640C (en) Novel canola protein isolate
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
WO2007052168A3 (en) Fed batch culture methods for streptococci
WO2006087637A3 (en) Anti her2/neu antibody
WO2011031020A3 (en) Method for preparing a fermented soybean meal using bacillus strains
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
WO2008023247A3 (en) Matrix attachment regions (mars) for increasing transcription and uses thereof
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
WO2006101441A8 (en) Method for protein purification comprising heat incubation in acetic acidic solution
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
DE602006006468D1 (de) Fixiertem und in paraffin eingebettetem gewebe
Tanambell et al. In vitro protein digestibility of RuBisCO from alfalfa obtained from different processing histories: Insights from free N-terminal and mass spectrometry study
Wang et al. Extraction and identification of internal granule proteins from waxy wheat starch
IL218442A0 (en) Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma
Zhang et al. Isolation and purification of alkaline keratinase from Bacillus sp. 50-3
Peng et al. Non–animal collagens as new options for cosmetic formulation
WO2021076574A3 (en) Fn3 domain-sirna conjugates and uses thereof
CN104774822A (zh) 幽门螺旋杆菌丝氨酸蛋白酶的制备方法
Li et al. Isolation and enzymatic characterization of the first reported hyaluronidase from Yak (Bos grunniens) testis
Singh et al. Simultaneous refolding and purification of a recombinant lipase with an intein tag by affinity precipitation with chitosan

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO